Company intelligence / Profile preview
OTR3
Paris, Ile-de-France, Franceotr3.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Commercial
01
Overview
OTR3 has initiated a Phase 2 clinical trial for OTR4132, a novel neuroprotector for acute ischemic stroke patients following thrombectomy. A first-in-human pilot study (MATRISS) was conducted across three centers in France, evaluating six escalating doses with promising results demonstrating favorable safety and efficacy[6].
- Therapeutic areas
- PulmonologyDermatologyOphthalmologyNeurology
- Modalities
- ReGeneraTing Agents (RGTA®)heparan sulfate mimeticsmatrix therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on OTR3.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTR3.